105 results on '"Ang, K.K."'
Search Results
2. Comparison Between IMRT and 3D CRT in Laryngeal Cancer Patients Treated on RTOG 0522
3. A Phase 3 Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Long-term Report of Efficacy and Toxicity
4. Real-time Peer Review Quality Assurance Conferences Incorporating Physical Examination for Head-and-Neck Cancer Radiation Therapy Result in Clinically Meaningful Target Volume Alteration: Results of a Prospective Volumetric Analysis
5. Long-term Outcomes from RTOG 99-03: Radiation Therapy With or Without Erythropoietin for Anemic Head-and-Neck Cancer Patients
6. RTOG 90-03: Final Report
7. United States Patterns of Radiation Oncology Practice in the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN) Study
8. Outcomes and Risk Factors in Patients Treated with Surgery and Postoperative Radiation Therapy Alone: A Subset Update of a Randomized Trial
9. IMRT for Oropharyngeal Carcinoma: Patient Outcomes and Patterns of Failure
10. Symptom Burden during Radiation Therapy and Chemoradiation for Head and Neck Cancer
11. Characteristics and Clinical Outcomes of Patients with Multiple Potentially HPV-Related Malignancies
12. Skin Culture and Treatment Results in Head and Neck Cancer Patients with Severe Radiation Dermatitis and Potential Suprainfection
13. Should Hypopharynx Cancer Continue to be Included in ‘Multi-head and Neck’ Trials within the RTOG?
14. A Gene Expression Signature Predicts Recurrence-free Survival and Overall Survival for High-risk Surgical-pathologic Head and Neck Squamous Cell Carcinomas following Post-operative Radiotherapy
15. A Phase II Study of Submandibular Salivary Gland Transfer to the Submental Space Prior to Start of Radiation Treatment for Prevention of Radiation-induced Xerostomia in Head and Neck Cancer Patients: Initial Report of RTOG – 0244
16. Pre- and Postinduction Chemotherapy Target Volume Delineation in Head and Neck Cancer: Preliminary Results from an Expert Panel
17. Patterns of Disease Recurrence following Radiation for Oropharyngeal Cancer
18. Correlating Survival with Radiographic Response to Radiotherapy for Head-and-Neck Cancer Patients: FDG-PET/CT is not Superior to CT Alone
19. Interfractional Movement of the Larynx and Oropharynx during Radiotherapy
20. Phase II Randomized Trial of Postoperative Chemoradiation Plus Cetuximab for High-risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234)
21. Inter-observer Contouring Variations of Head-and-Neck Anatomy
22. The TAME Risk Classification System: Acute Toxicity Burden and IPD Analysis of RTOG 90–03
23. A Region-of-Interest Analysis of Setup Uncertainties in Head and Neck Radiotherapy
24. 4 Year Experience of Intensity Modulated Radiotherapy (IMRT)for tumors of the Nasal Cavity, Paranasal Sinuses and Orbit
25. Phase II Study of Paclitaxel and Cisplatin in Combination with Split Course Concomitant Hyperfractionated Re-Irradiation in Patients with Recurrent Squamous Cell Cancer of the Head and Neck: Results of RTOG 99-11
26. The Relationship of Cetuximab-Induced Rash and Survival in Patients with Head and Neck Cancer Treated with Radiotherapy and Cetuximab
27. Long Term Outcomes of RTOG 90–03: A Comparison of Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinoma
28. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer
29. M.D. Anderson consensus guidelines for head and neck target volume determination and delineation
30. Comparison of intra-arterial cisplatin and radiation therapy (RT) to other radiation therapy oncology group (RTOG) regimens using standard or accelerated RT with or without concurrent chemotherapy in patients with stage IV-T4 head and neck cancer
31. Early postoperative paclitaxel followed by paclitaxel and cisplatin concurrent with radiation therapy (RT) (phase II trial RTOG H-0024) is well tolerated for patients with resected, high-risk squamous carcinoma of the head and neck (HNSCC)
32. Intensity modulated radiation therapy (IMRT) for metastatic cervical adenopathy from oropharynx carcinoma
33. Perineural invasion infers poor therapeutic outcome and prophylactic neck irradiation posts no benefit
34. Does immune compromised state influence tumor control in patients with epithelial skin cancer of the head and neck region?
35. Preliminary results of intensity modulated radiation therapy for small primary oropharyngeal carcinoma
36. Results of radiation for early-stage carcinoma of the oropharynx
37. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse
38. C225 anti-EGFR (Epidermal Growth Factor Receptor) antibody enhances the efficacy of docetaxel chemoradiotherapy
39. Sinonasal carcinoma with neuroendocrine differentiation: patterns of failure according to histologic phenotype
40. The impact of baseline nutritional support on treatment outcome in patients with locally advanced squamous cell cancer of the head and neck treated with definitive radiotherapy: report of the radiation therapy oncology group (RTOG) trial 90-03
41. Overexpression of the epidermal growth factor receptor (EGFR), as determined by EGFR immunostaining on tissue microarrays, fails to demonstrate prognostic value for patients with glioblastoma multiforme: a report from RTOG 7401, 7918, 8302, 8409, 9006, 9305, 9602, and 9806
42. Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas: preliminary results of a phase II trial of the RTOG (99-14)
43. Conventional vs modified fractionated radiotherapy. meta-analysis of radiotherapy in head & neck squamous cell carcinoma : a meta-analysis based on individual patient data
44. Post-operative radiation for maxillary sinus carcinomas in the modern era
45. VEGF (vascular endothelial growth factor) modulates the development of radiation myelopathy (RM) in rats
46. Cost-utility analysis of rtog 90-03: phase iii randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma
47. Microvessel density (mvd)≥60 does not predict for outcome in advanced head and neck squamous cell carcinoma (HNSCC): results of a prospective study from the RTOG 90-03 trial
48. 101 Impact of risk factors and total time for combined surgery and radiotherapy on the outcome of patients with advanced head and neck cancer
49. 98 Long term results of the concomitant boost fractionation schedule for treatment of oropharyngeal carcinoma
50. 1 A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: Preliminary results of RTOG 9003
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.